Is elevated fasting insulin with normal glucose and HbA1c a sign of compensatory hyperinsulinemia?

The physiological phenomenon of compensatory hyperinsulinemia is a well-established precursor to metabolic dysfunction, often manifesting years before conventional markers like fasting glucose or HbA1c reach pathological ranges.

Clinical and diagnostic evidence

Longitudinal data, including findings from the Whitehall II and PROMISE cohorts, indicate that fasting insulin levels and markers of insulin resistance (such as HOMA-IR) often begin to rise 4 to 7 years before the onset of clinical dysglycemia. In these early stages, fasting plasma glucose (FPG) and HbA1c remain within standard "normal" ranges because the pancreatic beta-cells are successfully overproducing insulin to overcome peripheral resistance. Studies have shown that individuals can maintain euglycemia (normal blood sugar) even while their fasting insulin levels are significantly elevated, masking the underlying progression toward type 2 diabetes.

Mechanistic explanations

The transition to insulin resistance involves a sophisticated adaptive response by the pancreas. To maintain metabolic homeostasis, pancreatic beta-cells undergo both functional and structural changes:

• Beta-cell adaptation: The cells increase their secretory capacity and can expand in mass to meet the higher demand for insulin.
• Glucose set-point shift: There is a lowering of the glucose set-point for insulin release, which allows the body to maintain higher circulating insulin levels even when blood glucose is not yet elevated.
• Peripheral resistance: This hyperinsulinemic state is the body's primary defense against decreased insulin sensitivity in skeletal muscle, adipose tissue, and the liver. However, this state is ultimately unsustainable and eventually leads to beta-cell exhaustion, at which point glucose levels begin to rise and HbA1c follows.

Clinical implications

Because standard screening often relies solely on HbA1c or fasting glucose, this early "hyperinsulinemic phase" is frequently overlooked. Identifying elevated fasting insulin in a 47-year-old male with otherwise normal glucose markers can provide a critical window for intervention. While universal thresholds for "elevated" fasting insulin in normoglycemic individuals are still debated, the upward trend is a clear indicator of metabolic stress.

Bottom line

Elevated fasting insulin in the presence of normal glucose and HbA1c is a scientifically supported marker of early insulin resistance. It reflects a compensatory state where the pancreas overworks to maintain normal blood sugar levels, signaling a high risk for future metabolic decline.